{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:01:02Z","timestamp":1769313662434,"version":"3.49.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/wnf.0b013e3182087d48","type":"journal-article","created":{"date-parts":[[2011,1,15]],"date-time":"2011-01-15T06:17:40Z","timestamp":1295072260000},"page":"8-16","source":"Crossref","is-referenced-by-count":40,"title":["A 52-Week Study of Gabapentin Enacarbil in Restless Legs Syndrome"],"prefix":"10.1097","volume":"34","author":[{"given":"Aaron L.","family":"Ellenbogen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G.","family":"Thein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Winslow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry M.","family":"Tolson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Liesse","family":"Lassauzet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"11","key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","article-title":"Restless legs syndrome prevalence and impact: REST general population study.","volume":"165","author":"Allen","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4065\/81.1.17","article-title":"Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.","volume":"81","author":"Bogan","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2003.07.005","article-title":"Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).","volume":"5","author":"Winkelman","year":"2004","journal-title":"Sleep Med"},{"issue":"9","key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease.","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"issue":"5","key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","article-title":"Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.","volume":"30","author":"Driver-Dunckley","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 ()-1-((alpha-isobutanoyloxyethoxy)carbonyl aminomethyl)-1-cyclohexane acetic acid, a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters.","volume":"311","author":"Cundy","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1212\/01.wnl.0000341770.91926.cc","article-title":"Randomized, double-blind, placebo-controlled trial of XP13512\/GSK1838262 in patients with RLS.","volume":"72","author":"Kushida","year":"2009","journal-title":"Neurology"},{"issue":"suppl 1","key":"R8-3-20210203","first-page":"S443","article-title":"A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome.","volume":"24","author":"Lee","year":"2009","journal-title":"Mov Disord"},{"issue":"6","key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4065\/mcp.2009.0700","article-title":"Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study.","volume":"85","author":"Bogan","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"R10-3-20210203","first-page":"1122","article-title":"A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics and tolerability of gabapentin enacarbil in subjects with restless legs syndrome.","volume":"49","author":"Zomorodi","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"23","key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"Helsinki: ethical principles for medical research involving human subjects.","volume":"284","year":"2000","journal-title":"JAMA"},{"issue":"6","key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale.","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"4","key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/sleep\/15.4.376","article-title":"Reliability and factor analysis of the Epworth Sleepiness Scale.","volume":"15","author":"Johns","year":"1992","journal-title":"Sleep"},{"issue":"10","key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"issue":"7-8","key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.sleep.2006.09.009","article-title":"A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome.","volume":"8","author":"Garcia-Borreguero","year":"2007","journal-title":"Sleep Med"},{"issue":"10","key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/mds.21050","article-title":"Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.","volume":"21","author":"Montplaisir","year":"2006","journal-title":"Mov Disord"},{"issue":"1","key":"R17-3-20210203","first-page":"92","article-title":"Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.","volume":"75","author":"Trenkwalder","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.sleep.2007.12.004","article-title":"Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).","volume":"9","author":"Partinen","year":"2008","journal-title":"Sleep Med"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-201101000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:52:16Z","timestamp":1618278736000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201101000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3182087d48","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}